Shanghai Pharmaceuticals (SHA:601607, HKG:2607) received approval from China's drug administration for the supplemental drug application of tranexamic acid injection after it passed the regulator's consistency evaluation, according to a Shanghai bourse filing on Tuesday.
The drug, which is used to treat bleeding caused by hyperfibrinolysis, was evaluated for its consistency in quality and efficiency.
The pharmaceutical company's Hong Kong shares rose less than 2% during morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.